Hemostemix Files for Ethics Approval of its Study of Vascular Dementia
Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has filed its Institutional Review Board (IRB) application for approval of its Phase 1 clinical trial titled "Treatment of Vascular Cognitive Impairment and Dementia with Angiogenic Cell Precursors (ACP-01)." The 102-page submission marks a critical milestone in expanding the therapeutic reach of ACP
Biotechnology, Pharmaceuticals, Health
2025-10-09 9:03 AM EDT | Hemostemix Inc.
American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and Exposition
Toronto, Ontario--(Newsfile Corp. - October 9, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary multi-factor analysis of telomeres, today announced that the American Society of Hematology ("ASH") has accepted Telo Genomics' abstract submission for a poster presentation during the upcoming 2025 Annual Meeting. Dr. Yulia Shifr
2025-10-09 8:30 AM EDT | Telo Genomics Corp.
InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. Neil Klompas, CPA, CA to its Board of Directors, effective immediately. Mr. Klompas brings over 30 years of experience in healthcare and biotechnology across operational
Biotechnology, Pharmaceuticals
2025-10-09 8:30 AM EDT | InMed Pharmaceuticals
OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting
New York, New York--(Newsfile Corp. - October 9, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "
2025-10-09 7:40 AM EDT | OS Therapies
Neural Portfolio Company Hanf.com Reports Strong Fiscal 2024 Results with 65% Revenue Growth, Positive Cash Flow and Double-Digit Operating Margin; Continued Growth in 2025; First Half Revenues Up 31% Year-Over-Year
Toronto, Ontario--(Newsfile Corp. - October 8, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on therapeutic solutions for mental health conditions, together with its portfolio company CWE European Holdings Inc. ("CWE", operating as Hanf.com), one of Germany's leading hemp- and CBD-based retail platforms, is pleased to report the audited financial results of Hanf.com for the fis
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-08 9:37 AM EDT | Neural Therapeutics Inc.
PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease
Phase 3 program targeting a potential US$2.2B U.S. market opportunity 505(b)(2) regulatory path leveraging prior human data to reduce risk, cost, and time FDA-reviewed CMC package validated through prior ANDA approval Patent coverage to 2036 for ketamine in Parkinson's and related motor disorders Active pharmaceutical partnering discussions Upcoming catalysts (Q4 2025 - Q2 2026):
Biotechnology, Pharmaceuticals
2025-10-08 8:00 AM EDT | PharmaTher Holdings Ltd.
Envoy Medical Announces up to $16 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
White Bear Lake, Minnesota--(Newsfile Corp. - October 8, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 3,007,524 shares of its Class A common stock at a purchase price of $1.33 per share, in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a
Biotechnology, Healthcare and Hospitals
2025-10-08 7:00 AM EDT | Envoy Medical, Inc.
Genix Pharmaceuticals Issues Clarification to Previously Announced Private Placement Terms
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") wishes to clarify an error in its news release dated September 04, 2025, regarding the Company's recently closed non-brokered private placement. The previous release incorrectly stated that the Units were issued at a price of $0.10 per Unit.
Biotechnology, Pharmaceuticals, Health
2025-10-07 5:48 PM EDT | Genix Pharmaceuticals Corp.
OS Therapies to Participate in Fall 2025 Conferences and Events
New York, New York--(Newsfile Corp. - October 7, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer
2025-10-07 11:50 AM EDT | OS Therapies
Hemostemix's Insider Lead Order of $330,000 Private Placement
Calgary, Alberta--(Newsfile Corp. - October 7, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce a lead order of $330,000 for a non brokered private placement of up to $700,000. Purchasers may subscribe for Units at $0.11. Each Unit consists of one Common Share and one Warrant. Each Warrant may be exercised by the holder to acquire one Common Share at $0.15 for a period of two years from the Closing Date, subje
Biotechnology, Pharmaceuticals, Health
2025-10-07 10:05 AM EDT | Hemostemix Inc.
BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that the company has been invited to participate in the landmark HANSE lung cancer screening trial in Germany. This strategic clinical collaboration with Prof. Dr. Jens Vogel-Claussen at Medizinische Hochschule Hannover, Prof. Dr. Martin Reck at
Technology, Biotechnology, Healthcare and Hospitals
2025-10-07 8:30 AM EDT | BioMark Diagnostics, Inc.
Envoy Medical Receives FDA Approval to Expand Its Pivotal Clinical Trial to Final Stage Based on Submission of Promising Three-Month Data
White Bear Lake, Minnesota--(Newsfile Corp. - October 7, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to expand the Company's pivotal clinical trial for the fully implanted Acclaim® cochlear implant to the final stage based on promising three-month data from the first 10 patients. The
Biotechnology, Healthcare and Hospitals
2025-10-07 8:00 AM EDT | Envoy Medical, Inc.
Cannabis Bioscience International Holdings, Inc. Appoints Veteran Financier Andy Trivedi to Its Board of Directors, Strengthening Capital Strategy and Growth Outlook
Houston, Texas--(Newsfile Corp. - October 6, 2025) - Cannabis Bioscience International Holdings, Inc., (OTCID: CBIH), a publicly traded biomedical cannabis research and development company listed on the OTC Markets under the ticker symbol CBIH, today announced the appointment of Mr. Andy Trivedi, MBA, to its Board of Directors. The addition of Mr. Trivedi marks a strategic step forward in the Company's mission to scale operations, expand access to capital, and enhance long-term shareholder va
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-10-06 7:00 AM EDT | Cannabis Bioscience International Holdings
Optimi Health's Psilocybin Capsules Selected for Medibank Insurance Program
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced that its 5mg naturally-derived psilocybin capsules have been selected for inclusion in Medibank's psychotherapy program, an AUD $10 million insurance-backed initiative that has now been expanded to cover Treatment-Resistant Depression ("TRD
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-06 7:00 AM EDT | Optimi Health Corp.
Aires Partnership with WWE Creates First-Ever EMF-Friendly WWE Wrestling Match & Measurable Business Results
Toronto, Ontario--(Newsfile Corp. - October 6, 2025) - American Aires Inc. (CSE:WIFI) (OTCQB:AAIRF) ("Aires" or the "Company"), a pioneer
2025-10-06 6:00 AM EDT | American Aires Inc.
Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce its participation at CPHI Worldwide 2025, taking place in Frankfurt, Germany from October 28-30, 2025. At this premier gathering and global trade fair of pharmaceutical leaders, Defence looks forward to engaging with potential partners acro
Biotechnology, Pharmaceuticals, Health
2025-10-06 3:15 AM EDT | Defence Therapeutics Inc.
Marvel Biosciences Announces Acceleration of Warrant Expiry Date
Calgary, Alberta--(Newsfile Corp. - October 3, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is announcing that, further to the Company's press releases of May 16, 2024, June 21, 2024 and July 19, 2024, the Company is formally providing notice that it will be accelerating the expiry date of the warrants issued in relation to its non-brokered private placement unit offering
2025-10-03 5:00 AM EDT | Marvel Biosciences Corp.
Canadian-made Stable Isotopes: TMC Group Attends EANM 2025 to Strengthen Global Supply Chains
Vancouver, British Columbia--(Newsfile Corp. - October 2, 2025) - TMC Group, a manufacturer of high-purity stable isotopes, is attending the European Association of Nuclear Medicine (EANM) 2025 Annual Congress, October 4-8 in Barcelona. TMC Group's enriched stable isotopes have been supporting groundbreaking scientific research and innovation around the world since 2004. "We've been quietly providing a safe, reliable supply of enriched stable isotopes to world-leading researchers and li
Technology, Biotechnology, Chemical, Pharmaceuticals
2025-10-02 10:00 AM EDT | TMC Group
Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Mark Lambermon, PhD, as Head of Quality and Operations. Dr. Lambermon brings over 20 years of experience spanning pharmaceutical R&D, biotech innovation, and commercial manufacturing, with a proven track record in building
Biotechnology, Pharmaceuticals, Health
2025-10-02 3:15 AM EDT | Defence Therapeutics Inc.
ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand
Boca Raton, Florida--(Newsfile Corp. - October 1, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("ENTO" or the "Company") today announced it has acquired 100% of GRID AI Corp ("GRID AI"), a grid-edge, AI-driven software and device platform that enables utilities, retailers, and large power users to dynamically manage load and distributed energy resources ("DERs"). Over $50 million has been invested since 2019 to commercialize this revolutionary autonomous platform delivering Dynamic
Biotechnology, Pharmaceuticals
2025-10-01 8:30 AM EDT | Entero Therapeutics, Inc.